tiprankstipranks
Analyst Profile
Followed by 284 other investors
.
Graig Suvannavejh

Graig Suvannavejh

Mizuho Securities
Wall Street Analyst
Ranked #4,564 out of 8,047 Analysts on TipRanks (#10,644 out of 21,521 overall experts)

Success Rate

49%
51 out of 104 Profitable Transactions

Average Return

0.50%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Graig Suvannavejh's ratings since 2012 and opened each position for the duration of 1 Year:
49.04% of your transactions would have been profitable with an average return of 0.5%

Stock Rating Distribution

198Ratings
50.51% Buy
44.44% Hold
5.05% Sell
Distribution of Graig Suvannavejh's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market
United KingdomUK Market
GermanyGermany Market

Best Rating

Stock:
Halozyme Therapeutics
(HALO)
Rating Type:Buy
Dates:Jan 08, 2020 - Jan 08, 2021
Gain:136.10%
The most profitable rating made by Graig Suvannavejh

Graig Suvannavejh's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Alkermes
Buy
Reiterated
$24.00
(-8.22% Downside)
100%
+32.80%
3
Fortress Biotech
Hold
Downgraded
$2.00
(57.48% Upside)
0%
-82.30%
3
Oramed Pharmaceuticals
Buy
Reiterated
$27.00
(184.81% Upside)
0%
-75.75%
2
Ligand Pharma
Buy
Reiterated
$96.00
(-9.74% Downside)
50%
-8.50%
2
Lumos Pharma
Buy
Reiterated
$45.00
(418.77% Upside)
100%
+38.78%
4
Alterity Therapeutics
Hold
Downgraded
$3.00
(397.93% Upside)
0.00%
1
Xoma
Buy
Upgraded
$7.00
(-65.14% Downside)
50%
+0.15%
3
EyePoint Pharmaceuticals
Buy
Initiated
$6.00
(-45.99% Downside)
100%
+3.00%
1
Keryx Biopharma
Buy
Reiterated
0%
-19.20%
1
Acura Pharmaceuticals
Hold
Downgraded
$1.00
(1328.57% Upside)
0%
-28.23%
4
List of latest recommendations made by Graig Suvannavejh. Click to expand and see Graig Suvannavejh's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More